BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
CORT upcoming catalysts
Corcept Therapeutics: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 2 FDA event(s). Subscribe to CORT (.ics).
Drugs: relacorilant, Nivolumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Corcept Therapeutics CORT | NCT03604198 Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | Cushing Syndrome | active not recruiting | 125 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-03-25 | FDA approval | approved | CORCEPT THERAP CORT | LIFYORLI | Approved 2026-03-25: LIFYORLI (COPACKAGED) (NDA220641 ORIG1) |
| 2026-01-28 | Complete response letter | complete response | Corcept Therapeutics CORT | relacorilant | CRL 2026-01-28: Corcept Therapeutics NDA 219398 (relacorilant capsules) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2 | Corcept Therapeutics CORT | NCT05407324 Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | active not recruiting | 279 |
| 2026-09 est. | P1/P2 | Corcept Therapeutics CORT | NCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | Neoplasms | recruiting | 50 |
| 2026-02-13 | P2 | Corcept Therapeutics CORT | NCT06108219 A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH) | completed | 175 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.